The fragile X mental retardation protein (FMRP) is an RNA-binding protein that controls translational efficiency and regulates synaptic plasticity. Here, we report that FMRP is involved in dopamine (DA) modulation of synaptic potentiation. AMPA glutamate receptor subtype 1 (GluR1) surface expression and phosphorylation in response to D1 receptor stimulation were reduced in cultured Fmr1 À/À prefrontal cortex (PFC) neurons. Furthermore, D1 receptor signaling was impaired, accompanied by D1 receptor hyperphosphorylation at serine sites and subcellular redistribution of G protein-coupled receptor kinase 2 (GRK2) in both PFC and striatum of Fmr1 À/À mice. FMRP interacted with GRK2, and pharmacological inhibition of GRK2 rescued D1 receptor signaling in Fmr1 À/À neurons. Finally, D1 receptor agonist partially rescued hyperactivity and enhanced the motor function of Fmr1 À/À mice. Our study has identified FMRP as a key messenger for DA modulation in the forebrain and may provide insights into the cellular and molecular mechanisms underlying fragile X syndrome.
INTRODUCTION
Dopamine (DA) in the prefrontal cortex (PFC) plays a critical role in cognitive functions and neuropsychiatric pathology (Huang et al., 2004; Seamans and Yang, 2004; Surmeier, 2007) . The DA input to PFC from the ventral tegmental area (VTA) regulates many aspects of working memory, planning, and attention, and its dysfunctions are suggested to contribute to neuropsychiatric disorders (Carlsson, 2001; Castner et al., 2000; Seamans and Yang, 2004) . DA functions in its target cells through five subtypes of DA receptors (D1-D5) (Huang and Kandel, 1995; West and Grace, 2002; Williams and Goldman-Rakic, 1995) . Understanding the signaling pathways of DA receptor-mediated modulation may provide new insights into the cellular mechanisms underlying various DA-associated mental disorders.
Fragile X syndrome is a common inherited mental retardation caused by the lack of fragile X mental retardation protein (FMRP) due to silencing of the FMR1 gene (Feng et al., 1995; Garber et al., 2006) . It has been proposed that FMRP may act as a local regulator for synaptic plasticity (Bagni and Greenough, 2005; Garber et al., 2006; Grossman et al., 2006) . Previously, we showed that FMRP is critical for NMDA receptor-dependent long-term potentiation (LTP) in the cingulate region of the PFC in trace fear memory (Zhao et al., 2005a) . Deficits in activity-dependent synaptic plasticity have also been observed in piriform cortices and the hippocampal CA1 region of Fmr1 À/À mice (Larson et al., 2005; Lauterborn et al., 2007) . Fragile X syndrome is often accompanied by neuropsychiatric disorders such as hyperactivity, attention disorders, and autism (Bagni and Greenough, 2005; Bear et al., 2004; Grossman et al., 2006) , suggesting that the lack of FMRP may affect DA function. However, no link between FMRP and DA modulation has been studied thus far. Here, we employed integrative approaches to demonstrate that FMRP contributes to DA modulation of AMPA glutamate receptor subtype 1 (GluR1) receptor synaptic insertion and dopaminergic facilitation of LTP. We found that the surface expression and phosphorylation of AMPA GluR1 receptors at the cAMP-dependent protein kinase (PKA) phosphorylation site induced by stimulating D1 receptors was attenuated in Fmr1 D2-type (D2-D4 subtypes) (Missale et al., 1998; Seamans and Yang, 2004) . In cultured rat cortical neurons, DA D1 receptors are positively coupled to the PKA signaling pathway through G s proteins and contribute to AMPA GluR1 receptor trafficking (Sun et al., 2005) . To determine whether DA also affects AMPA receptor functions in mouse PFC neurons, we treated cultured PFC neurons with the D1 receptor agonists SKF81297 and dihydrexidine or the D2 receptor agonists quinpirole and bromocriptine. Neither D1 nor D2 receptor agonists affected the total expression levels of GluR1 or GluR2/3 in cultures (see Figures S1A and S1B available online). Surface expression of GluR1 was increased after treatment with D1 receptor agonists but was decreased by D2 receptor agonists (p < 0.01 versus control, n = 4 dishes; Figure 1A ). Surface expression of GluR2 and 3 was unchanged ( Figure S1C ). The effect of D1 receptor agonists on GluR1 surface expression was blocked by the D1 receptor antagonist SCH23390 ( Figure 1B ). The D1 receptor agonist SKF81297 increased GluR1 surface expression in a dose-dependent manner ( Figure 1C ). These findings demonstrate that D1 receptor activation can facilitate the surface expression of AMPA GluR1 receptors.
The phosphorylation of the AMPA receptor GluR1 subunit plays a key role in its synaptic expression and synaptic plasticity (Esteban et al., 2003; Snyder et al., 2000) . We studied the phosphorylation of GluR1 by DA receptor activation at two sites: the PKA phosphorylation site at Ser845, and the PKC or calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylation site at Ser831 (Man et al., 2007; Snyder et al., 2000) . We compared the effect of D1 or D2 receptor agonists on the phosphorylation of GluR1 in cultured neurons and found that the phosphorylation of GluR1 at Ser845 was increased by D1 receptor agonists and decreased by D2 receptor agonists (p < 0.01 versus control, n = 4 dishes; Figure 1D ). In contrast, the phosphorylation level of GluR1 at Ser831 was not affected by either D1 or D2 receptor agonists ( Figure 1E ). The effect of D1 receptor agonists on the phosphorylation of GluR1 was blocked by the D1 receptor antagonist SCH23390 ( Figure 1F ), further supporting the idea that D1 receptor activation can induce phosphorylation of AMPA GluR1 at Ser845.
Requirement of FMRP for D1 Receptor Agonist-Produced Effects
To investigate the role of FMRP in DA receptor signaling, we tested the effects of the D1 agonist SKF81297 on GluR1 in cultured PFC neurons of Fmr1 À/À mice. We found that the surface expression of GluR1 triggered by SKF81297 in Fmr1 À/À PFC neurons was impaired compared to that of wild-type (WT) mice (WT, 2.25 ± 0.08; Fmr1 À/À , 1.42 ± 0.05; p < 0.05, n = 6 dishes; Figure 2A ). SKF81297 did not affect the total expression of GluR1 and GluR2/3 receptors in WT or Fmr1 À/À neurons ( Figures  S2A and S2B ). However, no difference in the total expression levels of GluR1 and GluR2/3 receptors was found between WT Surface biotinylation assays following treatment of cultured prefrontal cortical (PFC) neurons with D1 agonists (SKF81297 and dihydrexidine) or D2 agonists (quinpirole and bromocriptine) for 10 min at a concentration of 5 mM. n = 4 dishes per group; *p < 0.01 versus control. Data are normalized to the control values and are expressed as mean ± SEM. (A) GluR1 surface expression was increased after D1 agonist treatment, whereas it was decreased by D2 agonists. (B) The D1 antagonist SCH23390 (5 mM) blocked the increase in GluR1 surface expression following D1 agonist treatment. (C) Dose-dependent effect of the D1 agonist SKF81297 on GluR1 surface expression. The highest level of GluR1 surface expression was seen from 5 mM.
(D) GluR1 phosphorylation at Ser845 was increased by D1 agonist treatment but decreased by D2 agonists. (E) GluR1 phosphorylation at Ser831 was unchanged. (F) The D1 antagonist SCH23390 (5 mM) blocked increased GluR1 phosphorylation at Ser845 induced by D1 agonists. Figure 2A ; Figure S2C ). These results provide direct evidence that FMRP is involved in DA receptor signaling and contributes to GluR1 surface expression induced by D1 receptor activation. We next compared the D1 receptor agonist-triggered phosphorylation of GluR1 in WT and Fmr1 À/À neurons. While there was no difference in the basal phosphorylation of GluR1 at both Ser845 and Ser831 ( Figures 2B and 2C) , the increased phosphorylation of GluR1 receptors at Ser845 induced by D1 activation was almost abolished in Fmr1 À/À neurons (WT, 2.33 ± 0.09; Fmr1 À/À , 1.40 ± 0.05; p < 0.05, n = 6 dishes; Figure 2B ). The effect of FMRP deletion was relatively selective. SKF81297 did not affect the phosphorylation of GluR1 at Ser831 in Fmr1 À/À neurons ( Figure 2C ). We also found that the expression levels of D1 receptors in cultured PFC neurons of Fmr1 À/À mice were similar to that of WT mice ( Figure 2D ).
The homomeric GluR1 AMPA receptor has a faster decay time than heteromeric GluR2 AMPA receptors (Thiagarajan et al., 2005) . During electrophysiological recordings in cultured neurons, bath application of SKF81297 caused a significant decrease in the decay time of AMPA miniature excitatory postsynaptic currents (mEPSCs) (2.56 ± 0.31 ms, n = 12 cells; p < 0.05 versus control, 3.15 ± 0.15 ms, n = 12 cells) in WT PFC neurons, whereas the decay time was unchanged in Fmr1 À/À mice . These data provide functional evidence that synaptic GluR1 trafficking is altered by D1 receptor activation and that FMRP is required for DA-triggered GluR1 insertion.
FMRP can be rapidly translated in an activity-dependent manner (Hou et al., 2006; Weiler et al., 2004) . PSD-95, a key scaffolding protein involved in synaptic plasticity, modulates DA-mediated phosphorylation of AMPA receptors (Swayze et al., 2004) . FMRP contributes to group I metabotropic glutamate receptordependent translation of PSD-95 (Todd et al., 2003) . We found that neither FMRP nor PSD-95 expression levels were altered in cultured PFC neurons following D1 receptor activation (Figures S3D and S3E) , indicating that D1 receptor activation does not affect FMRP or PSD-95 expression.
Impaired Facilitation of Synaptic LTP by D1 Receptors in Fmr1
À/À Mice
The PFC, including its cingulate region, plays an important role in learning and memory, drug addiction, and pain (Courtney et al., 1998; Rainville et al., 1997; Zhao et al., 2005a; Zhuo, 2002) . To further test the effect of D1 receptor activation on synaptic plasticity, we performed whole-cell patch-clamp recordings in visually identified pyramidal neurons in the cingulate region of PFC slices from adult WT mice. Bath application of the D1 receptor agonist SKF81297 had no effect on basal synaptic transmission (105.7% ± 7.0%, n = 9 cells; Figure 3A ). We next paired D1 agonist application with an LTP induction protocol and found that bath application of SKF81297 for 10 min paired with the LTP induction protocol significantly enhanced the amplitude of LTP (176.4% ± 11.3%, n = 9 cells; p < 0.05 versus pairing training only; Figures 3B and 3C Both presynaptic and postsynaptic mechanisms contribute to LTP expression (Kandel, 2001; Malinow and Malenka, 2002; Nicoll and Malenka, 1995; Song and Huganir, 2002) . To determine whether presynaptic and/or postsynaptic mechanisms are involved in dopaminergic modulation of LTP, we measured paired-pulse facilitation (PPF) before and after perfusion of the D1 receptor agonist SKF81297 and LTP induction. The PPF (50 ms interval) was not altered ( Figures S4A-S4C ), suggesting that facilitation of LTP by D1 receptor activation in PFC likely depends on postsynaptic mechanisms. To confirm the role of GluR1 receptors in the facilitation of LTP by D1 receptor activation, we tested the effects of the GluR1 C-terminal peptide analog Pep1-TGL, which has been shown to interfere with GluR1-related synaptic potentiation (Hayashi et al., 2000) . Pep1-TGL has no effect on the basal AMPA receptor-mediated EPSCs . However, the facilitatory effects of SKF81297 on LTP were diminished by intracellular application of Pep1-TGL ( Figure 3D ), suggesting that incorporation of homomeric GluR1 receptors plays a critical role in the facilitation of LTP by D1 receptor activation. We also measured the effects of SKF81297 on NMDA receptor-mediated responses and found that bath application of SKF81297 did not affect NMDA EPSCs ( Figure 3E ). Therefore, the facilitation of LTP by D1 receptor activation is not likely due to its direct modulation of NMDA receptors. In addition, there was no difference in the expression levels of D1 receptors in PFC slices between WT and Fmr1 À/À mice ( Figure 3F ), and the affinity of D1 receptor agonist was not changed in PFC of Fmr1 À/À mice ( Figure 3G ). Thus, the impairment of DA-induced facilitation of synaptic potentiation is not due to a defect in D1 receptors.
Impaired D1 Receptor Signaling in PFC of Fmr1 À/À Mice D1 receptors preferentially couple to G s proteins, stimulating the activity of adenylyl cyclases (ACs) and PKA pathways (Huang and Kandel, 1995; Missale et al., 1998) . We determined the effect of the D1 receptor agonist SKF81297 on ACs with a cAMP assay and found that the increase in cAMP caused by SKF81297 was attenuated in both PFC neuronal cultures and slices from Fmr1 signaling pathway is selectively affected in the PFC of Fmr1
mice. We then checked the expression and function of Ga s protein in Fmr1 À/À mice and found no difference in the basal levels of Ga s protein in the PFC between Fmr1 À/À and WT mice ( Figure 4C ). In addition, the increase in cAMP level caused by the G protein activators GTP-g-S or NaF was not affected in PFC slices of Fmr1 À/À mice compared to WT mice ( Figure 4D ).
These results indicate that the expression and function of Ga s protein are not affected in PFC of Fmr1 À/À mice.
We next investigated the coupling of D1 receptors to Ga s by coimmunoprecipitation (Jones et al., 2000) . We found that coupling of D1 receptors to G s protein remained unchanged under basal conditions in PFC slices of Fmr1 À/À mice ( Figures 4E and   4F ). In contrast, the D1 receptor agonist SKF81297 increased the coupling of D1 receptors to Ga s protein in PFC slices of WT mice. Interestingly, the increase induced by SKF81297 was attenuated in Fmr1 À/À mice (p < 0.01 versus WT, n = 4 mice; Figures 4E and 4F) , indicating that coupling of D1 receptors to Ga s protein due to D1 receptor activation is impaired in PFC of Fmr1 À/À mice. D1 receptor phosphorylation modulates its interaction with G s proteins (Gainetdinov et al., 2004; Missale et al., 1998) . Here, we found that D1 receptor phosphorylation at serine sites was increased in PFC of Fmr1 À/À mice relative to WT mice (185.0% ± 15.3% of WT; p < 0.01, n = 4 mice; Figure 4G ), whereas the phosphorylation at tyrosine sites was not changed ( Figure 4G ). These data reveal that D1 receptors are hyperphosphorylated in PFC of Fmr1 À/À mice, which might account for the impaired coupling of D1 receptors to G s protein in Fmr1 À/À mice. There was no difference in cAMP levels after forskolin treatment between Fmr1 À/À and WT mice.
Cultured cortical neurons or slices were treated with 10 mM and 50 mM forskolin or 5 mM and 25 mM SKF81297 for 10 min. n = 6 wells in (A), n = 6 mice in ( GRKs phosphorylate GPCRs and modulate the efficacy of GPCR signaling pathways (Gainetdinov et al., 2004; Premont and Gainetdinov, 2007) . Previous studies have shown that DA receptors can be phosphorylated by GRKs (Gainetdinov et al., 2004; Premont and Gainetdinov, 2007) . We investigated the expression of GRKs in PFC and found that the total expression levels of GRK2 and GRK4-6 were not changed in PFC of Fmr1 À/À mice compared to WT mice ( Figure 4H) . Interestingly, the level of GRK2 in cell membrane preparation was increased, whereas it was decreased in cytosol preparation from PFC of Fmr1 À/À mice compared to WT mice (p < 0.01, n = 4 mice; Figures 4I and 4J) . However, the levels of GRK4-6 in both membrane and cytosol preparations were not changed ( Figures 4I  and 4J ). These results suggest that D1 receptor hyperphosphorylation might be caused by subcellular redistribution of GRK2 in PFC neurons of Fmr1 À/À mice and that GRK2 may be a key isoform of GRKs responsible for the impaired D1 receptor signaling in Fmr1 À/À mice.
FMRP Interacts with GRK2
FMRP interacts physically with other proteins (Hayashi et al., 2007; Menon et al., 2004) , and GRKs have been shown to interact with other nonreceptor proteins (Ribas et al., 2007) . We found that FMRP and GRK2 could interact with each other ( Figure 5A ). In contrast, FMRP did not interact with GRK4-6, D1 receptors, Ga s , GluR1, or 5-HT 7 receptors ( Figure 5B ). The interaction between FMRP and GRK2 was not due to nonspecific binding of antibodies, as shown in Figure 5C . FMRP was not present in the cell membrane, and the interaction between FMRP and GRK2 was only detected in the cytosol preparation of PFC ( Figure 5D ). Furthermore, we found that FMRP and GRK2 were colocalized in both the soma and dendrites of cultured PFC neurons ( Figure 5E ). These findings demonstrate that endogenous FMRP and GRK2 interact, suggesting that FMRP may regulate subcellular distribution of GRK2 through protein-protein interactions and that lack of FMRP leads to redistribution of GRK2 in PFC neurons of Fmr1 À/À mice.
D1 Receptor Signaling in Striatum of
To address whether D1 receptor signaling is specifically affected in PFC of Fmr1 À/À mice, we evaluated D1 receptor signaling in striatum, a key brain region receiving dopaminergic input (Centonze et al., 2003; Hallett et al., 2006; West and Grace, 2002) . We compared the effect of the D1 receptor agonist SKF81297 on ACs in the striatum between WT and Fmr1 À/À mice and found that the increase of cAMP was attenuated in striatal slices of Fmr1 À/À mice (p < 0.01, n = 4 mice; Figure 6A ). However, there was no difference in the cAMP increase caused by the AC activator forskolin or the 5-HT 7 receptor agonist AS19 between Fmr1 À/À and WT mice ( Figures 6A and 6B ). These results suggest that the coupling between D1 receptors and ACs is also affected in striatum of Fmr1 À/À mice. There was no difference in the basal levels of Ga s protein in striatum of Fmr1 À/À and WT mice ( Figure 6C ). The D1 receptor agonist SKF81297 increased coupling of D1 receptors to Ga s protein in striatal slices of WT mice, whereas this increase was attenuated in Fmr1 À/À mice (p < 0.01 versus WT, n = 4 mice; Figure 6D ). D1 receptors were hyperphosphorylated at serine sites (192% ± 13% of WT; p < 0.01, n = 4 mice; Figure 6E ), whereas phosphorylation at tyrosine sites was unchanged in striatum of Fmr1 À/À mice ( Figure 6F ).
Furthermore, we found that GRK2 was increased in membrane and decreased in cytosol preparations from striatum of Fmr1 À/À mice (p < 0.01, n = 4 mice; Figures 6G and 6H) . Finally, FMRP interacted with GRK2 in striatum ( Figure 6I ). These data point to an impairment of D1 receptor signaling in Fmr1 À/À striatum. Figure 7A ) resulted in increased membrane and decreased cytosolic expression of GRK2 ( Figure 7B ). The redistribution of GRK2 between membrane and cytosol was reversed by FMRP expression in Fmr1 À/À PFC neurons ( Figures 7C and 7D) . Consistently, expression of FMRP in Fmr1 À/À neurons reduced the increased D1 receptor phosphorylation at serine sites to a level similar to WT neurons ( Figures 7E and 7F ). In addition, FMRP expression reversed deficits in both coupling of D1 receptors to Ga s and cAMP production caused by the D1 receptor agonist SKF81297 in Fmr1 À/À PFC neurons ( Figures 7G-7I ). Application of SKF81297 caused a similar increase of GluR1 phosphorylation (Ser845) in WT and Fmr1 À/À PFC neuronal culture with FMRP expression ( Figure 7J ), with no difference in GluR1 surface expression ( Figure 7K ). These data demonstrate that FMRP expression rescues the alterations in D1 receptor signaling and its downstream effect on AMPA receptors in Fmr1 À/À neurons. and a GRK2 peptide inhibitor (Winstel et al., 2005) . Neither heparin nor the GRK2 peptide inhibitor affected D1 receptor phosphorylation at serine or tyrosine sites in cultured WT PFC neurons ( Figures 8A and 8B ). However, both heparin and the GRK2 peptide inhibitor could reduce D1 receptor hyperphosphorylation at serine sites in Fmr1 À/À neurons to levels similar to that of WT ( Figure 8C ). Furthermore, both heparin and the GRK2 peptide inhibitor could reverse deficits in coupling of D1 receptors to Ga s and cAMP production stimulated by the D1 receptor agonist SKF81297 in Fmr1 À/À PFC neurons ( Figures 8D and 8F ), although cAMP production in WT PFC culture was unaffected ( Figure 8E ). We also found that heparin and the GRK2 peptide inhibitor did not affect GluR1 phosphorylation (Ser845) or surface expression caused by SKF81297 in WT PFC neuronal culture (n = 4 dishes; Figure 8E ). However, they could reverse the deficits in GluR1 phosphorylation (Ser845) and GluR1 surface expression induced by SKF81297 in Fmr1 À/À neurons ( Figures 8H and 8I ). These results show that pharmacological inhibition of GRK2 can rescue D1 receptor signaling and its downstream effect on AMPA receptors in Fmr1 À/À neurons.
Rescue of D1 Receptor Signaling in
Another way to rescue D1 receptor signaling in Fmr1 À/À neurons is to directly activate ACs, bypassing D1 receptors. In PFC slices of WT mice, we found that coapplication of forskolin, an AC activator, with the D1 receptor agonist SKF81297 could cause further increase of cAMP compared to SKF81297 alone The GRK inhibitor heparin (10 mM) and GRK2 peptide inhibitor (2 mM) were applied to cultured PFC neurons at DIV16 in the presence of lipofectin (5 mg/ml). Experiments were carried out after 6 hr treatment with heparin or GRK2 peptide inhibitor. (p < 0.05, n = 4 mice; Figure S6A ), indicating that ACs can be further activated by forskolin in the presence of D1 receptor agonist. In Fmr1 À/À PFC slices, coapplication of forskolin and SKF81297 could further increase cAMP compared to SKF81297 alone (p < 0.01, n = 4 mice; Figure S6B ). The increase of cAMP caused by coapplication of forskolin and SKF81297 in PFC slices of Fmr1 À/À mice was similar to that caused by SKF81297 alone in WT PFC slices (p > 0.05, n = 4 mice; Figure S6B ). GluR1 phosphorylation (Ser845) and GluR1 surface expression induced by SKF81297 were impaired in Fmr1 À/À PFC slices compared to WT (p < 0.01, n = 4 mice; Figures S6C and  S6D ). However, when SKF81297 was coapplied with forskolin in Fmr1 À/À PFC slices, the increases of GluR1 phosphorylation (Ser845) and GluR1 surface expression were similar to those caused by SKF81297 alone in WT (p > 0.05, n = 4 mice; Figures  S6C and S6D ). Thus, D1 receptor signaling and its downstream effect on AMPA receptors can be rescued by stimulating ACs in Fmr1 À/À neurons.
The Effect of DA D1 Receptor Activation on Behavior of Fmr1 À/À Mice Fragile X patients and animal models exhibit behavioral phenotypes that are consistent with deficits in PFC function, such as hyperactivity, anxiety, and learning abnormalities (Bear et al., 2004; Moon et al., 2006; Ventura et al., 2004) . We analyzed locomotor activity in the open-field test to characterize hyperactivity, a common phenotype in fragile X syndrome. We found increased locomotor activity in Fmr1 À/À mice (p < 0.05, n = 8 mice for WT, n = 7 mice for Fmr1 À/À ; Figures 9A-9C) , and application of the D1 receptor agonist SKF81297 reduced this hyperactivity (p < 0.05, n = 7 mice for control, n = 8 mice for SKF81297; Figures 9D and  9E ). The locomotor activity in WT mice remained unaffected following SKF81297 injection ( Figures 9A-9C ). These data indicate that Fmr1 À/À mice exhibit hyperactivity and that excessive D1 receptor agonist can partially rescue this phenotype. We then investigated anxiety-like behaviors with the elevated plus-maze test. We found no differences between Fmr1 À/À and WT mice and no effect of SKF81297 ( Figures 9D and 9E ). These data indicate that anxiety-like behaviors are not detectable in this fragile X mouse model and suggest that these behaviors are probably not related to the D1 receptor signaling pathway. The striatum is involved in motor coordination and skill learning (Calabresi et al., 2007; Centonze et al., 2003; Schultz et al., 2003) . We investigated the motor function of the animals with the rotarod test and found that the D1 receptor agonist SKF81297, at a dose that did not affect the behavior of WT mice, could enhance the performance of Fmr1 À/À mice (p < 0.05, n = 8 mice for control, n = 7 mice for SKF81297; Figure 9F ). These data suggest that D1 receptor signaling might be altered in Fmr1 À/À mice, since these mice were more sensitive to excessive D1 receptor agonist. However, under basal conditions, there was no difference in motor function between Fmr1 À/À and WT mice ( Figure 9F ), which might be explained by the possible saturation of D1 receptor signaling.
DISCUSSION
We have provided strong evidence that FMRP acts as a key messenger for DA-mediated modulation of excitatory transmission in forebrain neurons. FMRP is required for surface expression of AMPA GluR1 receptors in response to D1 receptor activation. Facilitation of LTP by D1 receptor activation was consistently absent in the cingulate region of PFC of Fmr1 À/À mice. Previously, we reported that FMRP is required for NMDA receptor-dependent LTP in the cingulate region of PFC (Zhao et al., 2005a) . Together, our findings indicate that FMRP acts as a key messenger in both NMDA receptor-dependent LTP and DA receptor-mediated facilitation. FMRP is involved in DA signaling through its interaction with GRK2. Expressing FMRP in Fmr1 À/À neurons or inhibition of GRK2 rescued D1 receptor signaling in PFC. In addition, D1 receptor agonist partially rescued hyperactivity and enhanced motor function in Fmr1 À/À mice. These data indicate that FMRP acts as a messenger for the DA system in the forebrain.
FMRP, DA Modulation of AMPA Receptors, and Synaptic Potentiation D1 receptor activation has been reported to increase AMPA receptor surface expression and to facilitate AMPA receptors' synaptic insertion (Gao et al., 2006; Smith et al., 2005; Sun et al., 2005) . Here, we further compared the effects of D1 receptor activation on GluR1 surface expression in cultured PFC neurons to illustrate the role of FMRP in dopaminergic modulation of GluR1 receptors. We found that D1 receptor activation can increase GluR1 surface expression in PFC neurons, but this increase was significantly attenuated in Fmr1 À/À neurons. We also found that D1 receptor activation could induce GluR1 phosphorylation at the PKA phosphorylation site and that this induction was almost blocked in Fmr1 À/À PFC neurons. These results indicate that FMRP is involved in the regulation of GluR1 receptors by D1 receptors through the PKA signaling pathway.
Synapses in cingulate cortex undergo plasticity and are involved in higher brain functions such as learning and memory, drug addiction, and pain (Courtney et al., 1998; Frankland et al., 2004; Zhao et al., 2005b; Zhuo, 2002 Zhuo, , 2008 . The DA system modulates LTP and long-term depression (LTD) in PFC (Huang et al., 2004; Seamans and Yang, 2004) , and we found that D1 receptor activation facilitated cingulate prefrontal LTP through increased synaptic incorporation of homomeric GluR1. Unaltered PPF suggests that facilitation of LTP by D1 receptor activation in the cingulate PFC likely depends on a postsynaptic mechanism. However, we cannot rule out possible presynaptic modulation of inhibitory transmission (Kandel, 2001; Nicola and Malenka, 1997) , which was blocked in our recordings. Notably, D1 receptor activation facilitated LTP in WT mice but not in Fmr1 À/À mice, suggesting that GluR1 insertion induced by dopaminergic activation is impaired. These data reveal deficits in DA modulation of synaptic plasticity in Fmr1 À/À mice.
FMRP and D1 Receptor Signaling D1 receptors are positively coupled to ACs through G s proteins (Huang et al., 2004; Jaber et al., 1996; Missale et al., 1998) . We found that the coupling of D1 receptors to G s protein by D1 receptor activation is impaired in PFC of Fmr1 À/À mice. D1 receptor phosphorylation modulates interaction with G s proteins (Gainetdinov et al., 2004; Ribas et al., 2007) . We found that D1 receptor phosphorylation at serine sites was increased in PFC of Fmr1 À/À mice, which might account for the impaired coupling of D1 receptors to G s protein. DA D1 receptors can be phosphorylated by GRKs (Gainetdinov et al., 2004; Ribas et al., 2007) . We found that GRK2 levels were increased in the cell membrane but decreased in the cytosol in PFC The behavioral phenotypes of fragile X syndrome consist of hyperactivity, anxiety, autism, and cognitive deficits (Bear et al., 2004; Moon et al., 2006; Ventura et al., 2004) . Here, we found increased locomotor activity in Fmr1 À/À mice that could be reduced by D1 receptor agonist treatment. These data indicate that Fmr1 À/À mice are hyperactive and suggest this might be caused by defects in D1 receptor signaling. Since D1 receptor agonists typically activate locomotor activity (Heijtz et al., 2007) , it is interesting that SKF81297 reduced hyperactivity in Fmr1 À/À mice. However, this is consistent with the paradoxical ability of stimulants to alleviate hyperactivity in attention deficit hyperactivity disorder (ADHD), which is prevalent in fragile X patients (Arnsten, 2006; Sullivan et al., 2006) . Previously, amphetamine injection, which increases dopamine release, was shown to improve cognitive function in Fmr1 À/À mice (Ventura et al., 2004) . Taken together, these findings indicate that the dysfunction of the DA system could be an underlying mechanism for the behavioral phenotypes of fragile X syndrome.
In summary, we have shown that FMRP plays a key role in DA modulation of synaptic plasticity and DA-related behaviors. FMRP modulates D1 receptor signaling by regulating the subcellular distribution of GRK2. Our study has identified FMRP as a key messenger for DA modulation, at least in the forebrain, and may provide insights into the cellular mechanisms underlying fragile X syndrome.
EXPERIMENTAL PROCEDURES Animals

Fmr1 WT and Fmr1
À/À mice (male, 6-8 weeks of age) of the FVB.129P2-Fmr1tm1Cgr strain were used and maintained as described previously (Weiler et al., 2004; Zhao et al., 2005a) . The Animal Care and Use Committee of University of Toronto approved all mouse protocols.
Primary Neuronal Culture PFC neurons were prepared from postnatal day 0 (P0) using methods as described previously (Wang et al., 2007) . Cultures were used for experiments between 16 and 18 days in vitro (DIV). Cytosolic and membrane extracts were prepared from PFC slices or cultures of WT and Fmr1 À/À mice as described previously (Morozov et al., 2003) .
Transfection and Application of GRK2 Inhibitor in Neuronal Cultures
Cultured PFC neurons at DIV16 were transfected with FMRP expression vector or an empty vector (control) after reconstitution with NeuroPORTER transfection reagent (Sigma). Experiments were carried out on day 2 after transfection. The nonspecific GRK inhibitor heparin (10 mM) and GRK2 peptide inhibitor (2 mM) were applied to cultured PFC neurons at DIV16 in the presence of lipofectin (5 mg/ml) to facilitate their entry into cells. Assays were carried out after 6 hr of treatment.
Immunoprecipitation
For detection of D1 receptor phosphorylation, solubilized protein samples were prepared with modified RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF) and precipitated with 50 ml of protein G-agarose precoupled with anti-D1 receptor antibody for 4 hr at 4 C. The reaction mixtures were then washed three times, eluted by boiling in loading buffer, and subjected to western blot using antibodies to antiphosphoserine or anti-phosphotyrosine (BD Biosciences). For detection of protein-protein interactions by coimmunoprecipitation, protein samples from PFC were precleared by incubation with protein G-agarose, and D1 receptors or FMRP were precipitated with an anti-D1 receptor or anti-FMRP antibody, respectively (Chemicon). Immunocomplexes were captured with protein A-agarose for 4 hr, and pellets were washed four times and eluted by boiling in loading buffer. Proteins were separated on 4%-12% SDS-PAGE gels and probed with rabbit antibodies against Ga s (Upstate), GRK2 (Santa Cruz), GRK4-6 (Upstate), GluR1 (Chemicon), and 5-HT 7 receptors (Chemicon). HRP-conjugated secondary antibodies and enhanced chemiluminescence were used to detect proteins. Reaction mixtures without specific antibody were used for control.
Immunocytochemistry
Cultured PFC neurons were fixed at DIV18 with ice-cold 4% paraformaldehyde in PBS (pH 7.4) for 30 min, blocked with 3% normal goat serum plus 3% BSA in PBS for 2 hr, incubated with primary antibodies (FMRP antibody, 1:500; GRK2 antibody, 1:500) overnight, and then incubated with FITC-conjugated antimouse IgG and rhodamine-conjugated goat anti-rabbit IgG (Chemicon) diluted 1:500 in blocking solution. Coverslips were mounted onto slides with VECTA SHIELD mounting medium (Vector Laboratories). Staining was imaged and analyzed using Image-Pro Plus (Media Cybernetics, Inc.).
Surface Biotinylation Assay
Surface GluR1 and GluR2/3 receptors were detected by a biotinylation assay, followed by western blot analysis with GluR1 antibody (Upstate), anti-GluR2 and 3 (Chemicon), or pan-cadherin antibody (Sigma). At the end of SKF81297 treatment, ice-cold PBS (with calcium and magnesium, pH 7.4; Invitrogen) was added to prevent receptor internalization. After three washes with ice-cold PBS, cells were incubated in sulfo-NHS-LC-biotin (0.3 mg/ml in cold PBS; Pierce) for 30 min. Surface biotinylation was stopped by removal of the solution and incubation in 10 mM ice-cold glycine in PBS for 20 min. Cells then were washed three times with cold PBS and lysed by RIPA buffer, containing (in mM) 20 HEPES pH 7.4, 100 NaCl, 1 EGTA, 1 Na 3 VO 4 , 50 NaF, 1 mM 4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride, plus 1% NP-40, 1% deoxycholate, 0.1% SDS, 10 mg/ml leupeptin, and 1 mg/ml aprotinin. Biotinylated proteins were precipitated with 100 ml of ImmunoPure Immobilized Streptavidin (Pierce), separated on 4%-12% SDS-PAGE gels, and transferred to polyvinylidene fluoride membranes. Membranes were probed with anti-GluR1 antibody (1:3000), anti-GluR2 and 3 (1:3000), or anti-pan-cadherin antibody (1:1000), followed by peroxidase-conjugated goat anti-rabbit antibody (1:3000; Sigma). Immunoreactive bands were visualized by ECL (PerkinElmer Life Sciences). The density of immunoblots was quantified by NIH ImageJ software (http://rsbweb.nih.gov/ij/).
cAMP Assay For cortical neuron culture, cells were plated in 24-well tissue culture dishes. After treatment with forskolin (10 and 50 mM) or SKF81297 (5 and 25 mM) for 15 min, cells were harvested and lysed in 0.1 M HCl. Slices were incubated with forskolin (10 and 50 mM) or SKF81297 (5 and 25 mM) in artificial cerebrospinal fluid (ACSF; in mM: 124 NaCl, 4.4 KCl, 2 CaCl 2 , 1 MgSO 4 , 25 NaHCO 3 , 1 NaH 2 PO 4 , 10 glucose) and lysed in 0.1 M HCl. To determine the G proteinlinked response of AC activity, samples were stimulated by 100 mM GTP-g-S or 10 mM NaF. Phosphodiesterases were inhibited by the addition of 1 mM 3-isobutyl-1 methylxanthine (Sigma). Direct cAMP measurements were performed using a direct cAMP enzyme immunoassay kit (Assay Designs) according to the manufacturer's protocol. Experiments were terminated by rapid filtration, and filters were monitored for tritium. Nonspecific binding was defined in the presence of 10 mM (+)-butaclamol. Binding data were analyzed by the nonlinear least-square curve-fitting program KaleidaGraph (Synergy Software). For all experiments, direct assay comparisons between WT and Fmr1 À/À preparations were conducted on the same day, using the same serial drug dilutions, and on the same batch of tissue.
Electrophysiology PFC brain slices (300 mm) were prepared using standard methods (Wang et al., 2008; Wei et al., 2001) . Slices were transferred to a submerged recovery chamber containing oxygenated (95% O 2 /5% CO 2 ) ACSF at room temperature for at least 1 hr. Experiments were performed in a recording chamber on the stage of an Axioskop 2 FS microscope with infrared DIC optics for visualizing wholecell patch-clamp recordings. EPSCs were recorded from layer II-III neurons using an Axon 200B amplifier (Axon Instruments), and stimulations were delivered using a bipolar tungsten stimulating electrode placed in layer V of the prefrontal cortex, including the anterior cingulate cortex. EPSCs were induced by repetitive stimulations at 0.02 Hz, and neurons were voltage clamped at À70 mV. The recording pipettes (3-5 MU) were filled with solution containing (in mM) 145 K-gluconate, 5 NaCl, 1 MgCl 2 , 0.2 EGTA, 10 HEPES, 2 Mg-ATP, and 0.1 Na 3 -GTP (adjusted to pH 7.2 with KOH). After obtaining stable EPSCs for 10 min, three kinds of LTP induction paradigms were used within 12 min after establishing the whole-cell configuration to prevent washout effect on LTP induction. The first protocol involved paired presynaptic 80 pulses at 2 Hz with postsynaptic depolarization at +30 mV (referred to as pairing training). To test neuronal excitability, current clamp was used. Spikes were evoked by injecting depolarized current pulse (currents ranged from 100 to 150 pA to induce 3-4 spikes). To record the mEPSCs in culture neurons, 0.5 mM tetrodotoxin (TTX) was added in the bath solution. Picrotoxin (100 mM) was always present to block GABA A receptor-mediated inhibitory synaptic currents in slice recordings. To record NMDA receptor-mediated EPSCs, the AMPA receptor antagonist CNQX (20 mM) was also added, and holding potential was changed to À20 mV to release Mg 2+ blockade. The access resistance was 15-30 MU and was monitored throughout the experiment. Data were discarded if access resistance changed by more than 15% during an experiment.
Behavioral Experiments
An Activity Monitor system (43.2 3 43.2 3 30.5 cm; Med Associates) was used to record horizontal locomotor activity. Briefly, this system uses paired sets of photo beams to detect movement in an open field, and movement is recorded as beam breaks. The open field is placed inside a sound-attenuating chamber with dim illumination and a fan. Forty-five minutes after intraperitoneal injection of saline or SKF81297, each subject was placed in the center of the open field, and activity was measured for 30 min. The elevated plus maze (Med Associates) consisted of two open arms and two closed arms situated opposite each other, separated by a central platform. One hour after the open-field test, animals were individually placed in the center square and allowed to move freely for 5 min. Entries were defined as the mouse having all four paws on an arm. The number of entries and time spent on each arm was recorded. A video camera tracking system (EthoVision) was used to track the animals. The animals' motor functions were tested using the rotarod test. One hour before testing, animals were trained on a rotarod (Med Associates) at a constant velocity of 16 rpm until they could remain on for a 30 s period. The rotarod test was performed by measuring the time each animal was able to maintain its balance walking on the rotating drum. The rotarod accelerated from 4 to 40 rpm over a 5 min period. Mice were given three trials with a maximum time of 300 s and a 5 min intertrial rest interval. The latency to fall was taken as a measure of motor function. Some mice held on to the rotating drum instead of walking. For these mice, the latency to fall was recorded after two complete rotations.
Data Analysis
Results are expressed as mean ± SEM. For electrophysiology, statistical comparisons were performed using one-or two-way analysis of variance (ANOVA) using the Student-Newman-Keuls test for post hoc comparisons. For biochemistry data, unpaired or paired t tests were used for comparisons. In all cases, p < 0.05 was considered statistically significant.
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